Chart-Typ:
Zeitraum:
| JNJ Announces CHMP's Recommendation For Approval Of TECVAYLI | NEW BRUNSWICK (dpa-AFX) - Friday, Johnson & Johnson (JNJ) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of an... ► Artikel lesen |
| Die 120-Milliarden-Krise: Warum Psychodelika-Therapien gegen Depressionen "The next big thing" werden könnten | Anzeige / Werbung
Depression zählt zu den weltweit häufigsten psychischen Erkrankungen und gehört nach Einschätzung der Weltgesundheitsorganisation zu den führenden Ursachen für gesundheitsbedingte... ► Artikel lesen |
| Nanobiotix S.A.: NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer | All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was... ► Artikel lesen |
| Biogen Inc.: Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN | EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based... ► Artikel lesen |
| Biogen And Eisai Announce Japan Approval Of LEQEMBI Pen To Treat Early Alzheimer's Disease | WESTON (dpa-AFX) - Drug makers Biogen Inc. (BIIB) and Japan's Eisai Co., Ltd. (ESALY.PK, 4523.T, EII.SG) announced Wednesday that Japan has approved LEQEMBI Pen, the subcutaneous (SC) formulation... ► Artikel lesen |
| Biogen Inc.: LEQEMBI Pen (Subcutaneous Formulation of LEQEMBI) Approved in Japan for the Treatment of Early Alzheimer's Disease | TOKYO and CAMBRIDGE, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that "LEQEMBI Pen", the subcutaneous (SC) formulation of the anti-amyloid... ► Artikel lesen |
| AKTIEN IN FOKUS: Herzmittel-Flop drückt Novartis - Auch Ionis und Amgen schwach | ZÜRICH (dpa-AFX) - Der Misserfolg mit dem Herzmedikament Pelacarsen setzt am Montag gleich mehrere Aktien unter Druck. Zum einen die des Entwicklers Ionis Pharma und des Lizenznehmers Novartis und... ► Artikel lesen |
| Ionis Pharmaceuticals, Inc.: Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 | Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data in the management of severe hypertriglyceridemia (sHTG) will be presented at the European Society of Cardiology (ESC) Congress... ► Artikel lesen |
| Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BG MEDICINE INC finden Sie auf Wallstreet Online.